VRNA insider RSUs and options converted to cash at $107 per ADS
Rhea-AI Filing Summary
Verona Pharma plc (VRNA) director Christina Ackermann reported several transactions tied to the completion of a scheme of arrangement under a transaction agreement with Merck/Parent and Bidco. At the effective time, each ADS (representing eight Ordinary Shares) entitled holders to $107 in cash per ADS, based on $13.375 per Ordinary Share. Ms. Ackermann's outstanding time‑based RSUs and in‑the‑money options were accelerated and converted into cash under those terms. The Form 4 shows net disposals and conversions that left the reporting person with no direct beneficial ownership of Ordinary Shares or related options after the transactions.
Positive
- Accelerated conversion of RSUs provided immediate cash value at $13.375 per Ordinary Share
- In‑the‑money options cashed out converting option value into realized cash proceeds for the holder
Negative
- Reporting person's direct beneficial ownership reduced to zero following the Scheme of Arrangement
- Cash consideration subject to withholding taxes, which reduces net proceeds to the holder
Insights
Director's equity awards were cashed out at the transaction price, eliminating direct holdings.
The scheme paid $13.375 per Ordinary Share, equivalent to $107 per ADS because each ADS equals eight Ordinary Shares. Time‑based RSUs were accelerated and converted into a cash payment and certain share options with exercise prices below the ADS consideration were cashed out for their intrinsic value.
Key dependencies include the finalization of the Scheme of Arrangement and applicable withholding taxes; the transactions removed direct equity exposure for the reporting director as of 10/07/2025, which is observable immediately after the Effective Time.
Accelerated vesting and option cash‑outs are consistent with takeover deal mechanics.
RSUs covering ADSs were converted into cash equal to the ADS Consideration multiplied by the ADSs underlying each award. Share options with exercise prices of $1.9338 and $2.4288 were converted into cash equal to the excess of the ADS Consideration over the strike price per underlying ADS before withholding.
Investors should note the tax/withholding impact on net proceeds and that the director’s beneficial ownership shows zero direct shares or options after these closing adjustments as of 10/07/2025.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Share Unit | 72,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 200,000 | $0.00 | -- |
| Disposition | Share Options (Right to Buy) | 144,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 64,072 | $0.00 | -- |
| Exercise | Ordinary Shares | 72,000 | $0.00 | -- |
| Disposition | Ordinary Shares | 72,000 | $0.00 | -- |
Footnotes (1)
- Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding share option became fully vested, to the extent unvested, and at the Effective Time, each share option that had an exercise price less than the ADS Consideration was automatically converted into the right to receive an amount in cash equal to the product of (i) the aggregate number of ADSs underlying such share option and (ii) the excess, if any, of (a) an amount equal to the ADS Consideration over (b) the exercise price of such share option.
